|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||344.69 - 352.61|
|52 Week Range||268.62 - 372.61|
|Beta (3Y Monthly)||1.27|
|PE Ratio (TTM)||61.38|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||345.71|
Illumina, Inc. announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Ariosa Diagnostics, Inc.
Illumina, Inc. (ILMN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The Zacks Analyst Blog Highlights: American International, Arconic, Hasbro, Illumina and Jefferies
Is Illumina, Inc. (NASDAQ:ILMN) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]
Illumina Inc NASDAQ/NGS:ILMNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ILMN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $13.54 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.
Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing
Illumina, Inc. today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).
Illumina, Wix.com, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day
Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.